Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab vs rATG in De Novo Renal Transplant
NCT04311632Phase 2Completed
- Sponsor
- ITB-MED
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siplizumab in kidney transplant rejection (3 arms), sponsored by ITB-MED. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 at 12 months, Peak Plasma Concentration at 12 months and 1 more. Started May 2021; status: completed.
02
Drugs
siplizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04311632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311632.